טוען...
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Informa Healthcare
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3523809/ https://ncbi.nlm.nih.gov/pubmed/22738414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.706286 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|